Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
November 1, 1981Neurology

Administration of triamterene virtually abolished attacks in three separate single-blind trials totaling more than 12 months, and increased potassium levels significantly.

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Does triamterene prevent paralytic attacks in patients with hypokalemic periodic paralysis exacerbated by acetazolamide?

Population

3 patients (a father and two sons) with hypokalemic periodic paralysis exacerbated by acetazolamide

Comparison

Triamterene vs Acetazolamide

Design

Case_series, single-blind

Follow-up

more than 12 months

Authors

CTCarlos F. TorresRGRobert C. GriggsRMRichard T. Moxley

Discussion

Loading...

Member takes

Overview

May warrant trial in acetazolamide-exacerbated cases; hypothesis-generating and requires randomized confirmation.

Structured PICO

Does triamterene prevent paralytic attacks in patients with hypokalemic periodic paralysis exacerbated by acetazolamide?

P
Population
3 patients (a father and two sons) with hypokalemic periodic paralysis exacerbated by acetazolamide
I
Intervention
Triamterene
C
Comparator
Acetazolamide
O
Outcome
Attack frequency and severitypatient reported

Triamterene may be an effective treatment for patients with hypokalemic periodic paralysis who experience exacerbations with acetazolamide.

Cite This Study

Torres et al. (1981) studied this question.

synapsesocial.com/papers/6a707f533ce530166bc2d897https://doi.org/10.1212/wnl.31.11.1423
View Full Paper
Ask AI
Bookmark
Share